7JUN 2016


A New Partner for Global Health Innovative Technology (GHIT) Fund

GHIT Annual Partners Meeting 2016 held on June 7th, 2016

Otsuka Pharmaceutical participated in the Global Health Innovative Technology (GHIT) Fund as an associate partner on June 7th, 2016. GHIT Fund was established in April 2013 as the world's first product development fund specialized in Global Health through partnerships with the public (i.e. Japanese government), private, and civil sectors (Bill & Melinda Gates Foundation, etc.).

GHIT Fund contributes funds to research and development of pharmaceuticals or diagnostic products, etc. targeting the three major infectious diseases, HIV, tuberculosis and malaria; and neglected tropical diseases mainly prevalent in developing nations through utilization of the high standard technologies and innovations created in Japan.

In 3 years, over 60 projects were approved and over US$60 million has been invested. Of these projects, 7 have proceeded into the clinical development stages. It was announced during the G7 Ise-Shima Summit that an additional 130 million dollars would be invested to this foundation as a commitment of the Japanese government to global health.

Otsuka Pharmaceutical has challenged to overcome difficult global health problems and have been devoted to developing original, innovative products aimed at solving unmet medical needs. Given its long-term commitment, R&D investment, of over 30 years in the field of tuberculosis, it has successfully created a new anti-tuberculosis agent, delamanid, for the first time in approximately half a century. Our participation in GHIT Fund is anticipated to be highly valued as a further effort for our company in global health.

Global Project Leader Yoshitake talking about the need for public and private cooperation to expand use of delamanid

Earlier this year, Otsuka Pharmaceutical co-sponsored the 3rd Nikkei Asian Conference on Communicable Disease held in Tokyo.

A discussion on the theme "Japanese initiatives through new public and private cooperation" was held on cooperation between government and private sectors in regards to global expansion especially in Asia of Japanese technology conducive to managing infectious diseases.

Masuhiro Yoshitake, the Global Project Leader of TB Projects from Otsuka Pharmaceutical, presented the approval application status of delamanid, in each country and reported that cooperation between government and private sectors are essential within the international framework for global expansion of delamanid.

At the end of the conference, Dr. Shigeru Omi, Regional Director Emeritus for the World Health Organization Western Pacific Region, gave a summary "Tokyo Infectious Disease Statement 2016" in regards to recommendations based on this conference and challenges for the next year. He agreed that this will lead to future activities in both Japan and overseas.

Through participation in this conference, our company has been made aware of greater need for cooperation between government and private sectors in order to deliver our company's creation, delamanid, to patients.